6533b862fe1ef96bd12c767b
RESEARCH PRODUCT
Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.
Bárbara Soria-juanNatalia EscacenaVivian Capilla-gonzálezYolanda AguileraLucía LlanosJuan R. TejedoJuan R. TejedoFrancisco J. BedoyaFrancisco J. BedoyaVerónica JuanAntonio De La CuestaRafael Ruiz-salmerónEnrique AndreuLukas GrochowiczFelipe PrósperFermín Sánchez-guijoFrancisco S. LozanoManuel MirallesLourdes Del Río-soláGregorio CastellanosJosé M. MoraledaRobert SacksteinMariano García-arranzDamián García-olmoFranz MartínFranz MartínAbdelkrim HmadchaAbdelkrim HmadchaBernat SoriaBernat SoriaBernat SoriaThe Collaborative Working Group “Noma Project Team”subject
lcsh:Immunologic diseases. Allergycritical limb ischemiamedicine.medical_specialtyclinical trialsdiabetesbusiness.industrycost-effectivecell-based therapyImmunologyType 2 Diabetes MellitusCorrectionCritical limb ischemiamedicine.diseasecellular medicamentsCell therapyClinical trialDiabetes mellitusInternal medicinemedicineImmunology and Allergymedicine.symptombusinesslcsh:RC581-607description
[This corrects the article DOI: 10.3389/fimmu.2019.01151.].
year | journal | country | edition | language |
---|---|---|---|---|
2020-09-02 |